capAI PLC - Licence and Option Agreement for Ageotype
THIS ANNOUNCEMENT ("ANNOUNCEMENT") AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU, WHICH IS PART OF THE DOMESTIC LAW OF THE

capAI plc
(the "Company" and, together with its subsidiaries and subsidiary undertakings, the "Group" or "capAI")
Execution of Licence and Option Agreement with R42 Group for Ageotype Longevity Platform
capAI (LSE: CPAI, OTCQB: CPIQF), the applied artificial intelligence ("AI") venture platform, is pleased to announce that it has entered into a licence and option agreement (the "LOA") with R42 Group LLC ("R42") in respect of Ageotype, an AI-powered longevity and preventative health data platform. The LOA represents capAI's first platform within its capMedical vertical, following the licensing discussions with R42 referred to in the Company's announcement of
About Ageotype
Ageotype is a multi-modal health data platform, currently in beta, that integrates diverse sources of health data - including whole-body and brain MRI, blood-based metabolomics, multi-cancer early detection blood testing and gut microbiome analysis - into a single, AI-powered dashboard. The platform generates a personalised "Ageotype" classification, indicating which of a user's biological systems - brain, heart, metabolic, immune or microbiome - is aging fastest relative to their chronological age, together with plain-language, AI-generated insights and system-level tracking over time.
Ageotype is offered on a tiered commercial model, ranging from a free entry-level portal through to a premium annual programme combining comprehensive diagnostics, physician consultation and a personalised longevity roadmap. The platform was developed by R42 and has reached minimum viable product (MVP) status, with a live beta version and demonstration profile currently available to prospective users.
capMedical Strategy
Since the incorporation of capMedical in
The underlying Ageotype platform continues to evaluate potential business models, including additional product features and business-to-business (B2B) deployment environments, to broaden the range of commercial applications and partnership channels available to the Group.
Licensing discussions with R42 in respect of the Ageotype platform, referred to in the Company's announcement of
Principal Commercial Terms
Under the LOA, capAI has been granted an exclusive worldwide licence to develop and commercialise Ageotype and a discretionary option (the "Option") to acquire the associated intellectual property ("IP") for consideration of
capAI's licence period runs for 12 months from the date of the LOA, and is accordingly expected to expire on
Alliance Agreement
The LOA has been entered into pursuant to the strategic alliance agreement between the Company and R42 dated
Related Party Considerations
R42 is a venture capital firm founded and led by Professor
Substantial Property Transaction
The grant of the Option does not itself constitute a substantial property transaction for the purposes of section 190 of the Companies Act 2006 ("CA 2006"). However, if capAI elects to exercise the Option, such exercise would require R42 to transfer the Ageotype IP to capAI, and the Company to allot and issue new Ordinary Shares ("Consideration Shares") and/or, if regulatory constraints apply (e.g., Rule 9 of the
Pipeline of Further Opportunities
In addition to the LOA, the Board continues to evaluate a number of further potential opportunities within its stated capMedia and capMedical verticals, as well as in certain adjacent sectors, including applications with both medical and defence-related characteristics and other more defence-focused technologies. The Board notes that this pipeline encompasses businesses at varying stages of development, including certain more established operating companies, providing the Company with a broader range of potential strategic options consistent with its stated strategy. The majority of these opportunities involve existing R42 portfolio companies, with some also originating from other external parties.
These discussions are at an early stage, and there can be no certainty that any will result in a binding agreement. The Company will keep Shareholders updated as appropriate and in accordance with its legal and regulatory obligations.
Management Commentary
Professor
"Ageotype is the culmination of the licensing discussions we flagged to Shareholders in February, and I'm delighted it's now capMedical's first platform. The platform already integrates a genuinely broad set of health data - imaging, blood biomarkers, metabolomics and the microbiome - into a single longevity picture, and gives capAI a strong foundation to build out its preventative health offering. R42 looks forward to continuing to support capAI as it develops Ageotype toward commercial launch."
Further updates will be provided in due course.
For the purposes of
Enquiries
Company:
capAI plc hello@capaiplc.com
Broker:
AlbR Capital Limited Tel: +44 (0) 207 469 0930
Important Legal Information
The information contained in this Announcement is for background purposes only and does not purport to be full or complete, nor does this Announcement constitute or form part of any invitation or inducement to engage in investment activity. No reliance may be placed by any person for any purpose on the information contained in this Announcement or its accuracy, fairness or completeness. The contents of this Announcement are not to be construed as legal, financial, tax or medical advice, and Ageotype does not provide medical advice, diagnosis or treatment.
This Announcement does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any securities, nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with, any contract therefor.
This Announcement may include forward-looking statements, which are based on current expectations and projections about future events, including about the Group's operations, strategy, financial performance, development milestones, and the future prospects of its business divisions, including capMedia Inc, capMedical Inc, capMedia (UK) Ltd and capMedical (UK) Ltd. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target", "believe", "expect", "aim", "intend", "may", "anticipate", "estimate", "plan", "project", "will", "can have", "likely", "should", "would", "could" and any other words and terms of similar meaning or the negative thereof.
Forward-looking statements are based on current expectations and are subject to various risks and uncertainties that could cause actual outcomes to differ materially. These risks include, but are not limited to: successful execution of definitive agreements; regulatory approvals; development timelines; market acceptance; technological shifts; and broader economic conditions. No representation or warranty is made or will be made that any forward-looking statement will come to pass, and no assurance can be given that any forward-looking statement will prove accurate. Except as required by law, capAI undertakes no obligation to revise or update any forward-looking statement. The forward-looking statements in this Announcement speak only as at the date of this Announcement.
[1] Source: Fortune Business Insights, AI in Healthcare Market Size, Share | Growth Report [2026-2034]. https://www.fortunebusinessinsights.com/industry-reports/artificial-intelligence-in-healthcare-market-100534
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE